Home / Pharma News

Pharma News

Sun Pharma’s US operations partially on track

Sun Pharma announced on 19 September 2011 that its US arm has resolved issues raised by the country’s health regulator regarding violation of manufacturing standards.

Authorised generics implicated in pay-to-delay deals

A US Federal Trade Commission (FTC) report has found that authorised generics may reduce generics competition. The report also shows that some originator companies may have used agreements not to launch an authorised generic drug as a way to compensate would-be generic competitors for delaying entry into the market.

Eli Lilly in deal with Turkish generics company

American drugmaker Eli Lilly is in talks to form a partnership with, and potentially invest in, Turkish generic drugs company Mustafa Nevzat İlaç Sanayii A.Ş. (MN Pharmaceuticals), according to a Wall Street Journal report from 2 September 2011.

Medivir subsidiary BioPhausia sells generics business

Sweden-based Medivir announced on 25 August 2011 that its subsidiary BioPhausia had reached an agreement to sell its generics business (BMM Pharma) to Bluefish Pharmaceuticals (Bluefish) for SEK 26 million plus the value of inventories, some SEK 12 million. The staff of BMM Pharma will not be transferred in the acquisition.

GaBI Online launches its country focus section

- Provides Easy to Find Country Specific Information -

FIRST IN THE SPOTLIGHT – BELGIUM, THE NETHERLANDS AND UK

Generics of antibiotic Levaquin approved by FDA

The FDA has approved the first generic versions of Johnson and Johnson’s (J&J) blockbuster antibiotic Levaquin (levofloxacin), used to treat bacterial infections of the skin, sinuses, kidneys, bladder, and prostate caused by specific germs.

Record high drug shortages in the US

In 2010, there were 178 drugs that experienced shortages in the US, see Figure 1. This is a record high level and regulators blame quality and manufacturing problems for the crisis. Worse still, many of the drugs identified in 2010 remain unavailable or in short supply in 2011.

Watson buys Greek generic maker Specifar

Watson Pharmaceuticals announced on 25 May 2011 that it had bought the Greece-based generic manufacturer Specifar Pharmaceuticals for Euros 400 million with the intention of increasing its generics presence in Europe.

Pay-to-delay deals up by 60% in US

The number of deals struck between brand-name and generic pharmaceutical companies in the US are on the rise, despite efforts by the US Federal Trade Commission (FTC) to restrict agreements that delay the introduction of lower-cost medicines, according to a report from the agency.

Generics and biosimilars to drive down drug spending

A report published by IMS Health on 18 May 2011 predicts a slowing down of the growth in annual spending on medicines, with generics being one of the main contributing factors for this reduction.

Generics News Research General

more

Biosimilars News Research General

more